Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne Licenses Protein Synthesis Tech from MRC

NEW YORK (GenomeWeb) – Bio-Techne has licensed rights to a protein synthesis technology developed by the Medical Research Council Laboratory of Molecular Biology.

MRC Technology, the tech transfer organization for the UK's MRC, said that it has licensed to Bio-Techne the Genetically encoded Orthogonal Protection and Activated Ligation (GOPAL) technology, which enables the site-specific isopeptide bonds between proteins. The license enables the Minneapolis, Minn.-based life science research tools firm to develop reagent products using GOPAL.

According to MRC, the technology will first be applied to developing ubiquitin dimmers, with the potential for development of trimers and tetramers. It added that Bio-Techne's Boston Biochem company will investigate the use of GOPAL in "introducing post-translational modifications into proteins for structural and functional studies."

Financial and other terms of the license were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.